ISOVUE-M 300 Drug Patent Profile

When do Isovue-m 300 patents expire, and when can generic versions of Isovue-m 300 launch?

Isovue-m 300 is a drug marketed by Bracco and is included in one NDA.

The generic ingredient in ISOVUE-M 300 is iopamidol. There are eleven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iopamidol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Isovue-m 300

A generic version of ISOVUE-M 300 was approved as iopamidol by HAINAN POLY on February 27^th, 2023.

Summary for ISOVUE-M 300

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	20
Patent Applications:	3,591
DailyMed Link:	ISOVUE-M 300 at DailyMed

Recent Clinical Trials for ISOVUE-M 300

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
NYU Langone Health	N/A
National Cancer Institute (NCI)	N/A
M.D. Anderson Cancer Center	N/A

See all ISOVUE-M 300 clinical trials

Pharmacology for ISOVUE-M 300

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for ISOVUE-M 300

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	ISOVUE-M 300	iopamidol	INJECTABLE;INJECTION	018735-004	Dec 31, 1985	AP	RX	Yes	Yes

Expired US Patents for ISOVUE-M 300

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bracco	ISOVUE-M 300	iopamidol	INJECTABLE;INJECTION	018735-004	Dec 31, 1985

International Patents for ISOVUE-M 300

See the table below for patents covering ISOVUE-M 300 around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	8751675
Poland	96082
Mexico	5979
Romania	69615